Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Fig. 1

Identification of variants and pathway enrichment in PDX models. a We detected 1325 variations, including 581 nonsynonymous single-nucleotide variations, 225 CNVs, 513 indels, and 6 translocation fusions. b Genomic alterations were analyzed with different clinicopathological features. Navy, non-synonymous SNV; dark red, CNVs; yellow-green, frameshift indel; purple; inframeshift indel; and pink, fusion. c Genomic landscape analysis of genes altered in the PDX and TCGA datasets. Red, amplification; blue, deletion; and green, mutation. d Several relevant pathways, including the MAPK, ErbB, cell cycle, mTOR, and VEGF, were found to be enriched. e Details for molecular alterations involved in the ErbB and cell cycle pathway. Blue, amplification; green, mutation

Back to article page